Featured Research

from universities, journals, and other organizations

Chantix unsuitable for first-line smoking cessation use, study finds

Date:
November 3, 2011
Source:
Wake Forest Baptist Medical Center
Summary:
The poor safety profile of the smoking-cessation drug varenicline (Chantix) makes it unsuitable for first-line use, according to a new study. Varenicline, which already carries a "black box warning" from the U.S. Food and Drug Administration, showed a substantially increased risk of reported depression or suicidal behavior compared to other smoking-cessation treatments, according to researchers.

The poor safety profile of the smoking-cessation drug varenicline (Chantix™) makes it unsuitable for first-line use, according to a study published in the Nov. 2 edition of the journal PLoS ONE, an online publication of the Public Library of Science.

Varenicline, which already carries a "black box warning" from the U.S. Food and Drug Administration (FDA), showed a substantially increased risk of reported depression or suicidal behavior compared to other smoking-cessation treatments, according to researchers at Wake Forest Baptist Medical Center, the Institute for Safe Medication Practices, Harvard Medical School and Johns Hopkins University School of Medicine.

The researchers found that 90 percent of all reported suicides related to smoking- cessation drugs since 1998 implicated varenicline, even though it was on the market only four years in the nearly 13-year study period. They also found that varenicline was eight times more likely to result in a reported case of suicidal behavior or depression than nicotine replacement products.

"Our study contradicts the implications of a recent review by the FDA showing no difference in psychiatric hospitalizations between varenicline and nicotine replacement patches," said Curt D. Furberg, M.D., Ph.D., professor of Public Health Sciences at Wake Forest Baptist, co-author of the study and a nationally recognized leader in drug safety research. "The FDA hospitalization studies were flawed because they could not capture most of the serious psychiatric side effects, including suicide, depression, aggression and assaults. These can be catastrophic events but do not normally result in hospitalization.

"We found that Chantix is associated with more suicidal behavior reports than any other smoking-cessation drug on the U.S. market. The risks simply outweigh the benefits."

In this study, the team of scientists analyzed 3,249 case reports of serious injury included in the FDA's Adverse Event Reporting System from 1998 through September 2010 for self-injurious behavior or depression linked to varenicline, bupropion (Zyban™), an antidepressant approved for smoking cessation, and nicotine replacement products. They identified 2,925 (90 percent) cases of suicidal behavior or depression for varenicline, 229 (7 percent) for bupropion, and 95 (3 percent) cases for nicotine replacement products.

Furburg said that although a growing body of research from multiple sources establishes that varenicline substantially increases the risk of psychiatric side effects, it remains uncertain how frequently these events occur.

"While suicidal behavior or depression appear to be prominent side effects of varenicline, they are by no means the only safety issues," said Thomas J. Moore, senior scientist at the Institute for Safe Medication Practices and lead author of the study. "Varenicline has been associated with aggression and violence in three studies and carries a warning about this behavior. Its effects on vision, cognition and motor control and other risks have led to its being banned for airline pilots, air traffic controllers, military pilots and missile crews, and restricted for truck drivers."

Varenicline also is associated with an increase in the risk of serious cardiovascular events, as reported in the July 4, 2011, issue of the Canadian Medical Association Journal by Furberg and scientists at Wake Forest Baptist, Johns Hopkins University School of Medicine and the University of East Anglia in the United Kingdom.

"We strongly recommend that the FDA should revise the 'black box warning' to say what this study and the FDA's own data show -- that varenicline has higher risks for suicidal behavior and depression than other smoking-cessation treatments," Furberg said.

"We agree with the recommendations of the U.S. Veterans Administration (VA) that varenicline should be prescribed only after failure of nicotine replacement, bupropion or a combination," he added. "The VA also recommends a mental status examination to assess risk of suicidal or violent behavior prior to prescribing varenicline."

Tobacco use is responsible for one in five deaths in the United States each year and adds $193 billion to health care costs. It is among the most treatment-resistant forms of drug dependency, with 36 percent of the nation's smokers attempting to quit each year but only 3 percent succeeding for six months or more, according to the Department of Health and Human Services.

Along with Furberg and Moore, co-authors on the study are: Joseph Glenmullen, M.D., and John T. Maltsberger, M.D., of Harvard Medical School; and Sonal Singh, M.D., Ph.D., of Johns Hopkins University School of Medicine.


Story Source:

The above story is based on materials provided by Wake Forest Baptist Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas J. Moore, Curt D. Furberg, Joseph Glenmullen, John T. Maltsberger, Sonal Singh. Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE, 2011; 6 (11): e27016 DOI: 10.1371/journal.pone.0027016

Cite This Page:

Wake Forest Baptist Medical Center. "Chantix unsuitable for first-line smoking cessation use, study finds." ScienceDaily. ScienceDaily, 3 November 2011. <www.sciencedaily.com/releases/2011/11/111102190026.htm>.
Wake Forest Baptist Medical Center. (2011, November 3). Chantix unsuitable for first-line smoking cessation use, study finds. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2011/11/111102190026.htm
Wake Forest Baptist Medical Center. "Chantix unsuitable for first-line smoking cessation use, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/11/111102190026.htm (accessed July 26, 2014).

Share This




More Mind & Brain News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com
Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins